Central Nervous System
Central Nervous System
Zonisamide Rosemont 20mg/ml Oral Suspension
Zonisamide Rosemont is an anti-epileptic drug.
Zonisamide Rosemont 20mg/ml Oral Suspension is indicated for:
- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy (see section 5.1);
- adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
Central Nervous System
Zonisamide Rosemont 20mg/ml Oral Suspension
| Flavour | Strawberry |
| Storage Conditions | Do not store above 25°C. Store in the original package in order to protect from light. |
| Sucrose Free | |
| Shelf Life (Closed Bottle) | 18 Months |
| PIP Code | 1279801 |
| EAN Code | 5016119000980 |
| PEG/NG | Yes |
| Sodium Levels | Essentially sodium free |
Downloads
Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
Adverse events should also be reported to Rosemont at 0113 244 1400 or pharmacovigilance@rosemontpharma.com.
Contact us
For further product information and pricing please use the form below and a member of the team will be in touch
[contact-form-7 id="275" title="Contact form 1" html_class="two-col-contact-form"]Stay updated via our App
A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.
Related Products
